Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?

Cancer. 2019 Nov 1;125(21):3890-3891. doi: 10.1002/cncr.32381. Epub 2019 Jul 10.

Authors

Bernard L Marini¹, Anthony J Perissinotti¹, Dale L Bixby², Patrick W Burke², Kristen M Pettit², Lydia L Benitez¹

Affiliations

¹ Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, Michigan.
² Division of Hematology and Oncology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan.

PMID: 31291001
DOI: 10.1002/cncr.32381

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Bispecific
Humans
Inotuzumab Ozogamicin*
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Propensity Score

Substances

Antibodies, Bispecific
blinatumomab
Inotuzumab Ozogamicin